This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 4, 2000 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium |
Vol. 4 No. 1 |
6 |
The Psychology of Pain |
Vol. 4 No. 1 |
12 |
Opioids: A Review of the Pharmacology |
Vol. 4 No. 1 |
17 |
Fibromyalgia |
Vol. 4 No. 1 |
21 |
Compounding Intrathecal Medications |
Vol. 4 No. 1 |
24 |
Book Review: The NMDA Receptor |
Vol. 4 No. 1 |
26 |
Postherpetic Neuralgia |
Vol. 4 No. 1 |
27 |
Compounding Software: An Evaluation |
Vol. 4 No. 1 |
32 |
Marketing Your Prescription Compounding Practice: Part One |
Vol. 4 No. 1 |
36 |
Marketing Tip: Marketing Reps Can Help |
Vol. 4 No. 1 |
39 |
Profile of a Practice |
Vol. 4 No. 1 |
40 |
Particulates in Parenterals |
Vol. 4 No. 1 |
43 |
The Basics of Compounding: Compounding Medication Sticks |
Vol. 4 No. 1 |
44 |
Clear-Stick Base |
Vol. 4 No. 1 |
45 |
Styptic Pencil |
Vol. 4 No. 1 |
45 |
Styptic Pencil (Crayon Type) |
Vol. 4 No. 1 |
45 |
Analgesic Medication Stick |
Vol. 4 No. 1 |
45 |
Amitriptyline HCl 2% and Baclofen 2% in PLO |
Vol. 4 No. 1 |
50 |
Capsaicin 0.075%, Ketamine HCl 2% and Ketoprofen 10% in PLO |
Vol. 4 No. 1 |
51 |
Capsicum 0.32%, Methyl Salicylate 25% and Menthol 10% Analgesic Cream |
Vol. 4 No. 1 |
52 |
Clonidine HCl 1-mg/g in VanPen Cream |
Vol. 4 No. 1 |
53 |
Cyclobenzaprine 1% and Guaifenesin 10% in Speed Gel |
Vol. 4 No. 1 |
54 |
Dyclonine HCl 1-mg and Diphenhydramine HCl 10-mg Anesthetic Troches |
Vol. 4 No. 1 |
55 |
Fentanyl 50-mcg Chewable Gummy Gels |
Vol. 4 No. 1 |
56 |
Fentanyl 25-mcg/0.1-mL Nasal Spray |
Vol. 4 No. 1 |
57 |
Morphine Sulfate 2.5-mg/mL Inhalation Solution |
Vol. 4 No. 1 |
58 |
Shingles Ointment/Cream |
Vol. 4 No. 1 |
59 |
Stiffening Agents, Featured Excipient: |
Vol. 4 No. 1 |
60 |
Calculations |
Vol. 4 No. 1 |
63 |
Calibration of Hot Plates |
Vol. 4 No. 1 |
65 |
Stability of Alatrofloxacin Mesylate in 5% Dextrose Injection and 0.45% Sodium-Chloride Injection |
Vol. 4 No. 1 |
66 |
Naratriptan HCl in Extemporaneously Compounded Oral Suspensions |
Vol. 4 No. 1 |
69 |
Physicochemical Stability of Compounded Creams Containing alpha-Hydroxy Acids |
Vol. 4 No. 1 |
72 |
The Clinical Pharmacist's Role in Compounding for the Diabetic Patient |
Vol. 4 No. 2 |
84 |
Sugar Substitutes |
Vol. 4 No. 2 |
86 |
Complications of Diabetes |
Vol. 4 No. 2 |
88 |
Transdermal Gels in the Treatment of Diabetic Neuropathy |
Vol. 4 No. 2 |
91 |
L-Arginine and Ascorbic Acid for Diabetic Foot Ulcers |
Vol. 4 No. 2 |
94 |
Natural-Product Therapies for Treating Diabetic Neuropathy |
Vol. 4 No. 2 |
98 |
Patient Handout: Diabetes Management Guidelines |
Vol. 4 No. 2 |
100 |
Complementary Medicine - A Wellness Plan for People with Diabetes |
Vol. 4 No. 2 |
101 |
Diabetes Book Reviews |
Vol. 4 No. 2 |
103 |
Analytical Testing of Extemporaneously Compounded Preparations |
Vol. 4 No. 2 |
105 |
Natural Estrogens: A Review of the Primary Literature |
Vol. 4 No. 2 |
110 |
Marketing Your Prescription Compounding Practice: Part Two |
Vol. 4 No. 2 |
115 |
Profile of a Practice |
Vol. 4 No. 2 |
120 |
Basics of Compounding: Compounding Solutions |
Vol. 4 No. 2 |
122 |
Chlorhexidine 0.2% Oral Rinse |
Vol. 4 No. 2 |
128 |
Coenzyme Q10 200-mg Chewable Troches |
Vol. 4 No. 2 |
129 |
Diabetic Foot-Care Ointments |
Vol. 4 No. 2 |
130 |
Diabetic Skin-Ulcer Cream |
Vol. 4 No. 2 |
131 |
Ketamine HCl 5% and Amitriptyline HCl 2% in PLO |
Vol. 4 No. 2 |
132 |
Ketamine HCl 10%, Gabapentin 6%, Baclofen 2%, Amitriptyline HCl 2% and Clonidine HCl 0.1% in PLO |
Vol. 4 No. 2 |
133 |
Lipoic Acid 200-mg Chewable Troches |
Vol. 4 No. 2 |
134 |
Nifedipine 160-mg/mL in PLO |
Vol. 4 No. 2 |
135 |
Sugar-Free Suspension Structured Vehicle, USP |
Vol. 4 No. 2 |
136 |
Vanadyl Sulfate 10-mg Capsules |
Vol. 4 No. 2 |
137 |
Official Solvents, Featured Excipient: |
Vol. 4 No. 2 |
139 |
Standard Operating Procedure for Cleaning Glassware |
Vol. 4 No. 2 |
144 |
Calculations |
Vol. 4 No. 2 |
145 |
Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution |
Vol. 4 No. 2 |
146 |
Stability of Ranitidine Hydrochloride with Cefazolin Sodium, Cefbuperazone Sodium, Cefoxitin Sodium and Cephalothin Sodium during Simulated Y-Site Administration |
Vol. 4 No. 2 |
150 |
Effect of Some Antioxidants on the Color Change of White Lotion |
Vol. 4 No. 2 |
154 |
Compounding Ear, Nose and Throat Preparations |
Vol. 4 No. 3 |
164 |
Benzocaine Otic Solution |
Vol. 4 No. 3 |
165 |
General Nasal Solution Vehicle |
Vol. 4 No. 3 |
166 |
Desmopressin Acetate Nasal Solution 0.033 mg/mL |
Vol. 4 No. 3 |
167 |
Saline Nasal Mist |
Vol. 4 No. 3 |
167 |
Atropine Sulfate 0.5% Nasal Solution |
Vol. 4 No. 3 |
167 |
Xylometazoline 1-mg/mL HCl Nasal Drops |
Vol. 4 No. 3 |
169 |
Progesterone 20-mg/mL Nasal Solution |
Vol. 4 No. 3 |
169 |
Scopolamine Hydrobromide 0.4-mg per 0.1-mL Nasal Solution |
Vol. 4 No. 3 |
169 |
Xylitol in the Prevention of Otitis Media |
Vol. 4 No. 3 |
171 |
Xylitol 40% Syrup |
Vol. 4 No. 3 |
174 |
Xylitol Troches |
Vol. 4 No. 3 |
174 |
Sildenafil 0.2% Otic Drops |
Vol. 4 No. 3 |
175 |
Xerostomia |
Vol. 4 No. 3 |
176 |
Pilocarpine Oral Solution |
Vol. 4 No. 3 |
177 |
Pharmacological Treatment Options for Snoring |
Vol. 4 No. 3 |
179 |
Compounding OTC Drugs: A Legal Perspective |
Vol. 4 No. 3 |
180 |
Needleless Infusion Systems |
Vol. 4 No. 3 |
183 |
Pharmacy Licensure Requirements |
Vol. 4 No. 3 |
184 |
Wish You Were Here: Oklahoma Frontier Drug Store Museum |
Vol. 4 No. 3 |
188 |
Three Drug Stability Lives |
Vol. 4 No. 3 |
190 |
Cellulose Applications for the Pharmaceutical Industry |
Vol. 4 No. 3 |
196 |
Marketing Your Prescription Compounding Practice: Part Three |
Vol. 4 No. 3 |
199 |
Profile of a Practice: Surviving the Competition |
Vol. 4 No. 3 |
203 |
The Future of Compounding: An Industry Perspective |
Vol. 4 No. 3 |
204 |
Amphotericin B 100-mg Troches |
Vol. 4 No. 3 |
208 |
Dimethyl Sulfone 16% Nasal Solution |
Vol. 4 No. 3 |
209 |
Miconazole 2% Otic Powder |
Vol. 4 No. 3 |
210 |
Misoprostol 0.001% and Lidocaine 0.5% Oral Rinse |
Vol. 4 No. 3 |
211 |
Misoprostol 0.0027% Mucoadhesive Powder |
Vol. 4 No. 3 |
212 |
Mupirocin 1% Nasal Drops |
Vol. 4 No. 3 |
213 |
Nystatin 250,000-Unit and/or Tetracaine HCl 0.025% Popsicles |
Vol. 4 No. 3 |
214 |
Saliva Substitute for Dry Mouth/Throat |
Vol. 4 No. 3 |
215 |
Stomatitis Preparations |
Vol. 4 No. 3 |
216 |
Tonicity-Adjusting Agents, Featured Excipient: |
Vol. 4 No. 3 |
218 |
Calculations |
Vol. 4 No. 3 |
221 |
Assignment of Beyond-Use Dates |
Vol. 4 No. 3 |
222 |
Dry Heat Sterilization of Parenteral Oil Vehicles |
Vol. 4 No. 3 |
223 |
Stability of Morphine-Ketamine Mixtures in 0.9% Sodium Chloride Injection Packaged in Syringes, Plastic Bags and MEDICATION CASSETTEª Reservoirs |
Vol. 4 No. 3 |
225 |
Simple High-Performance Liquid Chromatographic Method for Simultaneous Determination of Fusidic Acid and Betamethasone Dipropionate in a Cream Formulation |
Vol. 4 No. 3 |
229 |
Stability of an Oral Liquid Dosage Form of Trovafloxacin Mesylate and Its Quantitation in Tablets Using High-Performance Liquid Chromatography |
Vol. 4 No. 3 |
233 |
Hospice and the Role of the Compounding Pharmacist |
Vol. 4 No. 4 |
246 |
Nausea and Vomiting in Hospice Patients |
Vol. 4 No. 4 |
250 |
Ketamine for Pain in Hospice Patients |
Vol. 4 No. 4 |
253 |
Custom-Making Medications for the Hospice Patient |
Vol. 4 No. 4 |
255 |
Body-Wash Formula |
Vol. 4 No. 4 |
255 |
Rinseless Shampoo |
Vol. 4 No. 4 |
255 |
Dry Mouth Spray |
Vol. 4 No. 4 |
255 |
Surviving Cancer - How the Compounding Pharmacist Can Help |
Vol. 4 No. 4 |
257 |
Compounding Using Hazardous Drugs |
Vol. 4 No. 4 |
261 |
Providing Positive Outcomes through Compounding for Animal Cancer Patients |
Vol. 4 No. 4 |
264 |
Nicotinamide-Adenine Dinucleotide (NADH) in Parkinson's Disease and Alzheimer's Disease |
Vol. 4 No. 4 |
276 |
NADH Capsules |
Vol. 4 No. 4 |
278 |
Short Communication: Compounding for Implantable Pumps |
Vol. 4 No. 4 |
280 |
Ambulatory Pumps: Part I of a Three-Part Series - Peristaltic Infusion Devices Review |
Vol. 4 No. 4 |
281 |
Profile of a Practice |
Vol. 4 No. 4 |
287 |
Book Reviews |
Vol. 4 No. 4 |
288 |
Basics of Compounding: Compounding Suppositories: Part I - Theoretical Considerations |
Vol. 4 No. 4 |
289 |
Dacarbazine 8-mg/mL, Doxorubicin HCl 0.8-mg/mL and Ondansetron 0.64-mg/mL injection |
Vol. 4 No. 4 |
296 |
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO |
Vol. 4 No. 4 |
297 |
Doxorubicin HCl 0.4-mg/mL, Ondansetron HCl 0.48-mg/mL and Vincristine Sulfate 14-mcg/mL Injection |
Vol. 4 No. 4 |
298 |
Fentanyl 100-mcg/0.1-mL and Promethazine HCl 12.5-mg/0.1-mL in PLO |
Vol. 4 No. 4 |
299 |
Fentanyl 35-mcg/mL, Bupivacaine HCl 1-mg/mL and Clonidine HCl 9-mcg/mL Intrathecal Solution |
Vol. 4 No. 4 |
300 |
Lidocaine HCl 2%, Misoprostol 0.003% and Phenytoin 2.5% Topical Gel for Decubitus Ulcers |
Vol. 4 No. 4 |
301 |
Misoprostol 0.0024% Mouth Rinse for Oral Ulcerations |
Vol. 4 No. 4 |
302 |
Morphine Sulfate 20-mg/mL and Clonidine HCl 10-mcg/mL Epidural Injection |
Vol. 4 No. 4 |
303 |
Nasogastric Tube/Percutaneous Endoscopic Gastrostomy Tube Suspension Formula |
Vol. 4 No. 4 |
304 |
Ondansetron HCl 8-mg/mL in PLO |
Vol. 4 No. 4 |
305 |
Capsule and Tablet Diluents, Featured Excipient: |
Vol. 4 No. 4 |
306 |
Basic Compounding Documentation: The Master Formula Form |
Vol. 4 No. 4 |
313 |
Calculations |
Vol. 4 No. 4 |
314 |
Experimenting with a New Emulsifying Agent (Tahini) in Mineral Oil Emulsion |
Vol. 4 No. 4 |
315 |
Microbiological Stability of a Fentanyl, Bupivacaine and Clonidine Mixture in a 0.9% Sodium Chloride Infusion Stored in Syringes and Reservoirs |
Vol. 4 No. 4 |
318 |
Stability of 5-Fluorouracil in an Extemporaneously Compounded Ophthalmic Solution |
Vol. 4 No. 4 |
320 |
Correction |
Vol. 4 No. 5 |
330 |
Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome |
Vol. 4 No. 5 |
334 |
Clinical Management and Review of Sjogren's Syndrome |
Vol. 4 No. 5 |
338 |
Sodium Fluoride Gel (0.5% Fluoride) |
Vol. 4 No. 5 |
339 |
Clotrimazole 10 mg Base A Troche |
Vol. 4 No. 5 |
339 |
Saliva Substitute |
Vol. 4 No. 5 |
340 |
Compounding with Beta-1, 3-D-Glucan |
Vol. 4 No. 5 |
342 |
Psoriasis |
Vol. 4 No. 5 |
346 |
Probiotics and Their Effect on Leaky Gut Syndrome and Associated Diseases |
Vol. 4 No. 5 |
349 |
Immune System Disorders: What's new and Interesting in Print and On-Line |
Vol. 4 No. 5 |
351 |
Transdermal Nifedipine for Wound Healing: Case Reports |
Vol. 4 No. 5 |
356 |
Wish You Were Here: Marvin Samson Center for the History of Pharmacy, University of the Sciences in Philadelphia |
Vol. 4 No. 5 |
359 |
Profile of A Practice: Hormone Replacement Therapy in the Heartland |
Vol. 4 No. 5 |
362 |
Ambulatory Syringe Infusion Devices: A Review - Part 2 |
Vol. 4 No. 5 |
364 |
Basics of Compounding: Compounding Suppositories Part 2 |
Vol. 4 No. 5 |
371 |
Artificial Tears for Dry Eyes |
Vol. 4 No. 5 |
376 |
Capsicum Oleoresin 0.3% and Ketoprofen 10% in PLO Gel |
Vol. 4 No. 5 |
377 |
Coal Tar Medication Stick |
Vol. 4 No. 5 |
378 |
Interferon with 0.1% Nonoxynol-9 Gel |
Vol. 4 No. 5 |
379 |
Interferon Ophthalmic Solution |
Vol. 4 No. 5 |
380 |
Pilocarpine HCl 2-mg Troches |
Vol. 4 No. 5 |
381 |
Psoriasis Nail Treatment |
Vol. 4 No. 5 |
382 |
Psoriasis Ointment, Heavy Moisturizing |
Vol. 4 No. 5 |
383 |
Sunscreen Gel-Alcoholic, SPF-15 |
Vol. 4 No. 5 |
384 |
Sunscreen Lotion, SPF-40 |
Vol. 4 No. 5 |
385 |
Providing Care for Diabetic Veterinary Patients |
Vol. 4 No. 5 |
386 |
Capsule and Tablet Lubricants, Featured Excipient: |
Vol. 4 No. 5 |
390 |
Calculations |
Vol. 4 No. 5 |
393 |
Basic Compounding Documentation: The Batch Control Sheet |
Vol. 4 No. 5 |
395 |
Stability of Hydrocortisone Sodium Succinate After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 4 No. 5 |
396 |
Stability of Lisinopril Syrup (2 mg/mL) Extemporaneously Compounded from Tablets |
Vol. 4 No. 5 |
398 |
Pharmaceutical Profile of Vitamin C Tablets and Capsules |
Vol. 4 No. 5 |
400 |
"Natural" Isomolecular Hormone Replacement: An Evidence-Based Medicine Approach |
Vol. 4 No .6 |
414 |
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens-Part 1 |
Vol. 4 No .6 |
421 |
Book Reviews: Women's Health |
Vol. 4 No .6 |
424 |
Hormone Replacement Therapy: Selected Recent References |
Vol. 4 No .6 |
426 |
Testosterone Deficiency in Men: New Treatments for Andropause |
Vol. 4 No .6 |
429 |
Compounded Testosterone Gels: A Guide for Clinicians and Pharmacists |
Vol. 4 No .6 |
432 |
Zinc Sulfate Heptahydrate 0.1% Solution |
Vol. 4 No .6 |
440 |
Managing Zinc Deficiency in an Office Setting |
Vol. 4 No .6 |
440 |
Disposable Ambulatory Infusion Devices: A Review - Part 3 |
Vol. 4 No .6 |
442 |
On-Line Billing for Custom Compounds: The Third-Party Payor |
Vol. 4 No .6 |
445 |
Fentanyl Troche Protocol |
Vol. 4 No .6 |
447 |
Profile of a Practice: Med Specialties Pharmacy |
Vol. 4 No .6 |
448 |
Wish You Were Here: Donald F. Salvatori California Pharmacy Museum |
Vol. 4 No .6 |
450 |
Basics of Compounding - Inhalation Preparations |
Vol. 4 No .6 |
452 |
Albuterol Sulfate 0.5% Inhalant Solution (Preservative Free) |
Vol. 4 No .6 |
455 |
Flunisolide 0.025% Inhalation Solution (Preservative Free) |
Vol. 4 No .6 |
455 |
Ipratropium Bromide 0.02% Solution (Preservative Free) |
Vol. 4 No .6 |
455 |
Terbutaline 0.1% Inhalant Solution (Preservative Free) |
Vol. 4 No .6 |
455 |
Albuterol-Cromolyn-Betamethasone for Inhalation (Preservative Free) |
Vol. 4 No .6 |
455 |
Albuterol-Ipratropium for Inhalation (Preservative Free) |
Vol. 4 No .6 |
455 |
Beclomethasone Dipropionate 0.042% Nasal Solution (Preservative Free) |
Vol. 4 No .6 |
455 |
Estriol and Estradiol 2.5-mg, Progesterone 50-mg, and Testosterone 1-mg Capsules |
Vol. 4 No .6 |
458 |
Estriol and Estradiol 1.25, 2.5, and 5-mg (BiEst) Capsules |
Vol. 4 No .6 |
459 |
Estrogen 0.625-mg/5-g Vaginal Gel |
Vol. 4 No .6 |
460 |
Progesterone Cycle Pack 35/50/75/100-mg Capsules |
Vol. 4 No .6 |
461 |
Testosterone 1-mg/0.1-mL Nasal Spray |
Vol. 4 No .6 |
462 |
Testosterone 1-mg/0.1-mL in a PLO Gel |
Vol. 4 No .6 |
463 |
Testosterone 1-mg/0.1-mL Topical Vaginal/Scrotal Spray |
Vol. 4 No .6 |
464 |
Triple Estrogen 2.5-mg/0.1-mL PLO |
Vol. 4 No .6 |
465 |
Triple Estrogen 2.5-mg/0.1-mL Sublingual Drops |
Vol. 4 No .6 |
466 |
Triple Estrogen 2.5-mg Tablet Triturates |
Vol. 4 No .6 |
467 |
Estrogen Use in Dogs: Indications and Complications |
Vol. 4 No .6 |
468 |
Oleaginous Vehicles, Featured Excipient: |
Vol. 4 No .6 |
470 |
Calculations |
Vol. 4 No .6 |
473 |
Assignment of a Beyond-Use Date for Compounded Preparations |
Vol. 4 No .6 |
474 |
Compatibility and Stability of Linezolid Injection Admixed with Gentamicin Sulfate and Tobramycin Sulfate |
Vol. 4 No .6 |
476 |
Stability of Nafcillin Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 4 No .6 |
480 |
Stability of Levothyroxine Sodium Injection in Polypropylene Syringes |
Vol. 4 No .6 |
482 |